Does the Rechallenge with Another CDK 4/6 Inhibitor in Breast Cancer Work? A Case Report and Literature Review

Does the Rechallenge with Another CDK 4/6 Inhibitor in Breast Cancer Work? A Case Report and Literature Review

Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors and endocrine therapy are the gold standards for systemic therapy for patients with hormone-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) metastatic breast cancer. Following progression, no prospective randomized data exi...

Full description

Bibliographic Details
Main Authors: Ioana-Miruna Stanciu, Cristina Florina Pirlog, Andrei-Wilhelm Anghel, Andreea Ioana Parosanu, Cristina Mihaela Olaru, Cristina Orlov-Slavu, Ion Cristian Iaciu, Ana Maria Popa, Radu Constantin Vrabie, Cornelia Nitipir
Format: Article
Language:English
Published: MDPI AG 2023-04-01
Series:Medicina
Subjects:
CDK4/6 inhibitors
CDK4/6 rechallenge
CDK4/6 toxicity
ribociclib
abemaciclib
Online Access:https://www.mdpi.com/1648-9144/59/4/696

Internet

https://www.mdpi.com/1648-9144/59/4/696

Similar Items